Identical twins or stepbrothers? How much similarity can we expect between the methodologies of the EU-HTA Joint Clinical Assessment (JCA) and the German benefit assessment?
According to the new EU-HTA regulation, the JCA of novel oncologic medicines and ATMPs is going to start as soon as January 2025. The methodological guidance for the JCA has been published recently. As expected, the methodologies of the JCA and the German benefit assessment for innovative pharmaceuticals seem similar, since the German IQWiG was involved in their development. In this webinar, we work out the commonalities and the differences of both concepts. Moreover, we discuss the possible impact of the new guidances for the JCA on the German benefit assessment in the near future.